TD Asset Management Inc Has $11.52 Million Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

TD Asset Management Inc lifted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 47.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 369,023 shares of the company’s stock after acquiring an additional 118,075 shares during the period. TD Asset Management Inc’s holdings in Teva Pharmaceutical Industries were worth $11,517,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of TEVA. Allworth Financial LP lifted its holdings in shares of Teva Pharmaceutical Industries by 53.8% during the fourth quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares in the last quarter. Grove Bank & Trust raised its stake in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after purchasing an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after purchasing an additional 345 shares in the last quarter. Global Retirement Partners LLC raised its stake in Teva Pharmaceutical Industries by 27.3% in the fourth quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock valued at $42,000 after purchasing an additional 292 shares in the last quarter. Finally, 1620 Investment Advisors Inc. raised its stake in Teva Pharmaceutical Industries by 1,823.2% in the fourth quarter. 1620 Investment Advisors Inc. now owns 1,577 shares of the company’s stock valued at $49,000 after purchasing an additional 1,495 shares in the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Down 2.8%

Shares of NYSE TEVA opened at $33.24 on Tuesday. The company has a current ratio of 1.01, a quick ratio of 0.78 and a debt-to-equity ratio of 1.70. The company has a market cap of $38.22 billion, a price-to-earnings ratio of 24.99, a PEG ratio of 3.49 and a beta of 0.84. Teva Pharmaceutical Industries Ltd. has a 12 month low of $14.99 and a 12 month high of $37.35. The stock has a 50-day moving average price of $32.89 and a two-hundred day moving average price of $31.74.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%. As a group, analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently commented on TEVA. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a research note on Saturday. JPMorgan Chase & Co. boosted their price target on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Barclays boosted their price target on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Bank of America boosted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, April 9th. Finally, Truist Financial boosted their price target on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, April 30th. Nine research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and a consensus target price of $41.78.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Mark Sabag sold 144,180 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $34.99, for a total transaction of $5,044,858.20. Following the completion of the transaction, the insider owned 80,760 shares of the company’s stock, valued at approximately $2,825,792.40. The trade was a 64.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Amir Weiss sold 10,679 shares of the business’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the transaction, the chief accounting officer directly owned 20,016 shares of the company’s stock, valued at approximately $720,576. The trade was a 34.79% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 421,470 shares of company stock valued at $14,570,945. Corporate insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.